Literature DB >> 12055392

Vascular endothelial growth factor: the key mediator in pleural effusion formation.

Carolyn S Grove1, Y C Gary Lee.   

Abstract

Pleural effusion is common in clinical practice. Increased vascular permeability and leakage play a principal role in the development of exudative pleural effusions. In vitro and in vivo evidence have solidly established vascular endothelial growth factor (VEGF), a potent inducer of vascular permeability, as a crucial mediator in pleural fluid formation. VEGF is present in high quantities in human effusions. In the pleural space, mesothelial cells, infiltrating inflammatory cells, and (in malignant pleuritis) cancer cells contribute to the VEGF accumulation in the pleural fluids. Pleural fluid VEGF is biologically active and may promote tumor growth and chemotaxis. Strategies to antagonize the VEGF activity at various target points of its signaling pathway have shown success in vitro and in animal models of malignant pleural or peritoneal effusions. Novel agents targeting VEGF activities are undergoing clinical trials. Regulation of VEGF activity and vascular permeability represent a rapidly expanding field of research, which is likely to provide further insight in the pathophysiology of pleural fluid formation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055392     DOI: 10.1097/00063198-200207000-00009

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  31 in total

1.  Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT.

Authors:  Rahul Bhatnagar; Ramon Luengo-Fernandez; Brennan C Kahan; Najib M Rahman; Robert F Miller; Nick A Maskell
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

2.  A potential role for VEGF in the diagnostic approach of pleural effusions.

Authors:  Aggeliki Psatha; Demosthenes Makris; Theodora Kerenidi; Zoe Daniil; Theodoros Kiropoulos; Konstantinos Gourgoulianis
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.

Authors:  Thomas S Uldrick; Kathleen M Wyvill; Pallavi Kumar; Deirdre O'Mahony; Wendy Bernstein; Karen Aleman; Mark N Polizzotto; Seth M Steinberg; Stefania Pittaluga; Vickie Marshall; Denise Whitby; Richard F Little; Robert Yarchoan
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

Review 4.  Pleural effusion.

Authors:  A R Medford; A Medford; N Maskell
Journal:  Postgrad Med J       Date:  2005-11       Impact factor: 2.401

5.  Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.

Authors:  Da-Wei Wu; Wei-An Chang; Kuan-Ting Liu; Meng-Chi Yen; Po-Lin Kuo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

6.  Increased expression of aquaporin-1 on the pleura of rats with a tuberculous pleural effusion.

Authors:  Hongchun Du; Canmao Xie; Qiao He; Xiaohua Deng
Journal:  Lung       Date:  2007-09-18       Impact factor: 2.584

7.  Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions.

Authors:  Eva Ruiz; Carmen Alemán; José Alegre; Jasone Monasterio; Rosa Ma Segura; Lluis Armadans; Ana Vázquez; Teresa Soriano; Tomás Fernández de Sevilla
Journal:  Lung       Date:  2005 May-Jun       Impact factor: 2.584

8.  Serum vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion.

Authors:  Seong Hwan Choi; Eun Young Park; Hye Lim Jung; Jae Won Shim; Deok Soo Kim; Moon Soo Park; Jung Yeon Shim
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 9.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

10.  Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.

Authors:  Mahtab Moayeri; Diana Haines; Howard A Young; Stephen H Leppla
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.